IMT-358

**IMT-358** is an investigational, proprietary glucose-insulin-potassium metabolic stabilization therapy developed by IMMEDIATE Therapeutics for rapid intravenous administration at first medical contact in acute coronary syndrome. The fixed-dose GIK formulation is intended to support myocardial cellular energy balance during early ischemia, before definitive reperfusion, with the goal of reducing downstream myocardial injury, cardiac arrest, heart-failure hospitalization, and mortality. The program is supported by the NIH-funded IMMEDIATE trial of early intravenous GIK and is described by the developer as Phase 3-ready with FDA Breakthrough Therapy designation for acute coronary syndrome. ([immtx.com](https://immtx.com/))

Other names

glucose-insulin-potassiumGIK solutionIMMEDIATE trial GIK